Cassava Sciences Inc (SAVA): A Technical Analysis
SAVA has 36-month beta value of -0.58. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,”
SAVA has 36-month beta value of -0.58. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,”
The 36-month beta value for SAVA is also noteworthy at -0.63. There are mixed opinions on the stock, with 0 analysts rating it as a
The stock of Cassava Sciences Inc (NASDAQ: SAVA) has increased by 6.84 when compared to last closing price of 28.51.Despite this, the company has seen
Company’s 36-month beta value is -0.63.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as
Additionally, the 36-month beta value for SAVA is -0.61. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0
The stock has a 36-month beta value of -0.55. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as
Cassava Sciences Inc. (SAVA) grew significantly in the past year. A Phase II study of a new Alzheimer’s treatment received a positive response from investors.
© 2024, Powered by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.